Trump gets experimental drug aimed at curbing severe illness
Antibody cocktail is in late-stage testing and its safety and effectiveness are not yet known, but maker Regeneron says it might reduce the period symptoms last
The experimental antibody drug given to US President Donald Trump has been called one of the most promising approaches to preventing serious illness from a COVID-19 infection.
Its maker, Regeneron Pharmaceuticals Inc., said the company agreed to supply a single dose, given through an IV, for Trump at the request of his physician under “compassionate use” provisions, when an experimental medicine is provided on a case-by-case emergency basis, while studies of it continue.
The new drug is in late-stage testing and its safety and effectiveness are not yet known. No treatment has yet proved able to prevent serious illness after a coronavirus infection.
Trump was given the experimental drug at the White House on Friday before he was taken to Walter Reed National Military Medical Center, where he’ll be monitored, officials said. So far, Trump has had only mild symptoms, including fatigue.
Several physicians who treat COVID-19, including Dr. David Boulware at the University of Minnesota, had speculated that doctors might use the antibody drug, given that this approach has worked against other diseases in the past.
“They’re not going to just sit around and watch to see if he gets sick,” Boulware said.
How antibodies work
Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help the immune system eliminate it. Vaccines trick the body into thinking there’s an infection so it makes these antibodies.
But it can take weeks for them to form after natural infection or a vaccine. The drugs aim to give that protection immediately, by supplying concentrated versions of one or two antibodies that worked best against the coronavirus in lab and animal tests.
Regeneron’s drug contains two antibodies to enhance chances that it will work. The company previously developed a successful Ebola treatment from an antibody combo.
What’s known so far
The drug is given as a one-time treatment through an IV. In multiple studies, Regeneron is testing it both for preventing infection and in people already infected, like Trump, to try to prevent serious illness or death.
Earlier this week, Regeneron said partial results from about 275 COVID-19 patients who were not sick enough to need hospitalization suggested it might be cutting how long symptoms last and helping reduce the amount of virus patients harbor.
However, the study has not been completed, the results were only announced in a company news release and have not been published or reviewed by other scientists.
Trump’s other treatments
Trump’s physician, Dr. Sean Conley, said Trump also was taking zinc, vitamin D, an antacid called famotidine, melatonin and aspirin. None of those have been proven to be effective against COVID-19.
Trump apparently is not receiving hydroxychloroquine, a drug he widely promoted that has been shown in many studies to be ineffective for preventing or treating COVID-19.
Do you rely on The Times of Israel for accurate and insightful news on Israel and the Jewish world? If so, please join The Times of Israel Community. For as little as $6/month, you will:
- Support our independent journalism;
- Enjoy an ad-free experience on the ToI site, apps and emails; and
- Gain access to exclusive content shared only with the ToI Community, including weekly letters from founding editor David Horovitz.
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel eleven years ago - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
David Horovitz, Founding Editor of The Times of Israel